[HTML][HTML] The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of …
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …
with NSCLC and have led to unprecedented improvements in response rates and survival in …
Tumour mutational burden: clinical utility, challenges and emerging improvements
Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous
mutations present within the cancer genome, varies across and within cancer types. A first …
mutations present within the cancer genome, varies across and within cancer types. A first …
[HTML][HTML] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C …
S Peters, R Dziadziuszko, A Morabito, E Felip… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with …
AN Bartley, AM Mills, E Konnick… - … of pathology & …, 2022 - meridian.allenpress.com
Context.—The US Food and Drug Administration (FDA) approved immune checkpoint
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …
Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after …
KI Zhou, B Peterson, A Serritella, J Thomas… - Clinical Cancer …, 2020 - AACR
Purpose: Intrapatient heterogeneity of programmed death ligand 1 (PD-L1) expression and
tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) could …
tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) could …
[HTML][HTML] Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in …
A Stenzinger, V Endris, J Budczies… - Journal of Thoracic …, 2020 - Elsevier
Introduction Tumor mutational burden (TMB) is a quantitative assessment of the number of
somatic mutations within a tumor genome. Immunotherapy benefit has been associated with …
somatic mutations within a tumor genome. Immunotherapy benefit has been associated with …
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
Background Advanced cholangiocarcinoma has a poor prognosis. Molecular targeted
approaches have been proposed for patients after progression under first-line …
approaches have been proposed for patients after progression under first-line …
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
J Budczies, M Kirchner, K Kluck, D Kazdal… - …, 2021 - Taylor & Francis
Immune checkpoint blockade (ICB) expands the therapeutic options for metastatic lung
cancer nowadays representing a standard frontline strategy as monotherapy or combination …
cancer nowadays representing a standard frontline strategy as monotherapy or combination …
Fusion‐positive non‐small cell lung carcinoma: biological principles, clinical practice, and diagnostic implications
D Kazdal, V Hofman, P Christopoulos… - Genes …, 2022 - Wiley Online Library
Based on superior efficacy and tolerability, targeted therapy is currently preferred over
chemotherapy and/or immunotherapy for actionable gene fusions that occur in late‐stage …
chemotherapy and/or immunotherapy for actionable gene fusions that occur in late‐stage …